The JUQ-103 offers a range of benefits that make it an attractive solution for businesses and organizations. Some of the most significant advantages of this technology include:
: Her career was recognized in May 2022 when she was ranked 16th in the "2022 Current AV Actress SEXY General Election" by Asahi Geinō.
| Property | Detail | |----------|--------| | | Cannabinoid receptors CB₁ (central nervous system) and CB₂ (peripheral immune tissues) | | Binding affinity | Reported in vitro Ki values are in the low‑nanomolar range (≈ 2–10 nM for CB₁; ≈ 5–15 nM for CB₂) – comparable to many first‑generation synthetic cannabinoids | | Functional activity | Full agonist at both CB₁ and CB₂ (produces maximal receptor activation) | | Typical effects (human) | Euphoria, sedation, altered perception, tachycardia, appetite changes; at higher doses can cause anxiety, paranoia, vomiting, seizures | | Metabolism | Predominantly hepatic via CYP3A4 and CYP2C9; major metabolites include hydroxylated and carboxylated species that may retain activity | | Duration of action | Oral/insufflated routes: 2–6 h of noticeable psychoactive effect; metabolites can be detectable in urine for 24–48 h |
The JUQ-103 offers a range of benefits that make it an attractive solution for businesses and organizations. Some of the most significant advantages of this technology include:
: Her career was recognized in May 2022 when she was ranked 16th in the "2022 Current AV Actress SEXY General Election" by Asahi Geinō. JUQ-103
| Property | Detail | |----------|--------| | | Cannabinoid receptors CB₁ (central nervous system) and CB₂ (peripheral immune tissues) | | Binding affinity | Reported in vitro Ki values are in the low‑nanomolar range (≈ 2–10 nM for CB₁; ≈ 5–15 nM for CB₂) – comparable to many first‑generation synthetic cannabinoids | | Functional activity | Full agonist at both CB₁ and CB₂ (produces maximal receptor activation) | | Typical effects (human) | Euphoria, sedation, altered perception, tachycardia, appetite changes; at higher doses can cause anxiety, paranoia, vomiting, seizures | | Metabolism | Predominantly hepatic via CYP3A4 and CYP2C9; major metabolites include hydroxylated and carboxylated species that may retain activity | | Duration of action | Oral/insufflated routes: 2–6 h of noticeable psychoactive effect; metabolites can be detectable in urine for 24–48 h | The JUQ-103 offers a range of benefits that
Supported by:
